Halozyme Therapeutics (HALO) to Release Quarterly Earnings on Tuesday

Halozyme Therapeutics (NASDAQ:HALO) will be releasing its earnings data after the market closes on Tuesday, May 7th. Analysts expect Halozyme Therapeutics to post earnings of $0.64 per share for the quarter. Halozyme Therapeutics has set its FY24 guidance at $3.55 to $3.90 EPS and its FY 2024 guidance at 3.550-3.900 EPS.Investors that wish to listen to the company’s conference call can do so using this link.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). The company had revenue of $230.04 million for the quarter, compared to analysts’ expectations of $235.25 million. Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. On average, analysts expect Halozyme Therapeutics to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Halozyme Therapeutics Stock Up 0.2 %

HALO stock opened at $39.91 on Monday. Halozyme Therapeutics has a 52 week low of $29.85 and a 52 week high of $45.00. The company has a quick ratio of 5.50, a current ratio of 6.64 and a debt-to-equity ratio of 17.89. The firm has a 50-day simple moving average of $39.99 and a 200-day simple moving average of $37.91. The stock has a market capitalization of $5.07 billion, a P/E ratio of 18.91, a P/E/G ratio of 0.47 and a beta of 1.26.

Analyst Ratings Changes

A number of brokerages have recently issued reports on HALO. The Goldman Sachs Group lowered their price target on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating on the stock in a research note on Thursday, January 18th. TheStreet lowered shares of Halozyme Therapeutics from a “b-” rating to a “c+” rating in a research report on Monday, January 22nd. StockNews.com upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, February 23rd. TD Cowen initiated coverage on Halozyme Therapeutics in a report on Thursday, February 29th. They set an “outperform” rating and a $54.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Halozyme Therapeutics in a research report on Tuesday, April 30th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $53.29.

Insider Activity

In related news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $39.55, for a total transaction of $395,500.00. Following the completion of the transaction, the senior vice president now owns 156,558 shares of the company’s stock, valued at approximately $6,191,868.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 30,000 shares of company stock valued at $1,196,800 in the last quarter. Insiders own 2.70% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.